Next Article in Journal
Factors Associated with the Breast Cancer Diagnostic Interval across Five Canadian Provinces: A CanIMPACT Retrospective Cohort Study
Next Article in Special Issue
Enhanced Recovery after Surgery (ERAS) Program for Patients with Peritoneal Surface Malignancies Undergoing Cytoreductive Surgery with or without HIPEC: A Systematic Review and a Meta-Analysis
Previous Article in Journal
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences
Previous Article in Special Issue
Laparoscopic Cytoreduction Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Surface Malignancies (PSM): Italian PSM Oncoteam Evidence and Literature Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 15
Issue 2
10.3390/cancers15020407
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Commentary
Peer-Review Record

Diagnostic and Therapeutic Pathway of Advanced Ovarian Cancer with Peritoneal Metastases

Cancers 2023, 15(2), 407; https://doi.org/10.3390/cancers15020407
by Valentina Ghirardi 1,*, Anna Fagotti 1, Luca Ansaloni 2, Mario Valle 3, Franco Roviello 4, Lorena Sorrentino 5, Fabio Accarpio 6, Gianluca Baiocchi 7, Lorenzo Piccini 8, Michele De Simone 9, Federico Coccolini 10, Mario Visaloco 11, Stefano Bacchetti 12, Giovanni Scambia 1 and Daniele Marrelli 4
Reviewer 1: Anonymous
Reviewer 2:
Karin Stålberg
Cancers 2023, 15(2), 407; https://doi.org/10.3390/cancers15020407
Submission received: 10 November 2022 / Revised: 27 December 2022 / Accepted: 30 December 2022 / Published: 7 January 2023
(This article belongs to the Special Issue Peritoneal Surface Malignancies (PSM): The SICO (Italian Society of Surgical Oncology) PSM—Oncoteam Experience, Result Analysis, and Studies’ Purpose)

Round 1

Reviewer 1 Report

The review titled: 

Diagnostic and therapeutic pathway of advanced ovarian cancer with peritoneal metastases by Valentina Ghirardi et al. is a comprehensive review.  The review article would benefit from a figure and table of treatments and outcomes to emphasize need for individual treatment. 

Author Response

Reviewer #1: Diagnostic and therapeutic pathway of advanced ovarian cancer with peritoneal metastases by Valentina Ghirardi et al. is a comprehensive review.  The review article would benefit from a figure and table of treatments and outcomes to emphasize need for individual treatment.

Answer: Thank you for your comment. Figure 1 which depicts diagnostic and treatment pathway for advanced ovarian cancer has been implemented , as asked.

Reviewer 2 Report

This is a well written, concise paper that gives the reader an updated overview over the topic of selecting the right treatment for patients with advance ovarian cancer.

However, the discussion and the conclusion do not really add that many novelties to already existing reviews. The authors have a tendency to cite papers within a narrow group of authors (including themselves), and a broader approach might have been of value. By adding a more detailed discussion concerning, for example, the treatment choice in different histologic ovarian cancer types, or BRCA pos/neg patients, the paper would be more forward-looking, in my opinion. Further, surgery in recurrent ovarian cancer was not mentioned. 

Author Response

Reviewer #2: This is a well written, concise paper that gives the reader an updated overview over the topic of selecting the right treatment for patients with advance ovarian cancer.

However, the discussion and the conclusion do not really add that many novelties to already existing reviews. The authors have a tendency to cite papers within a narrow group of authors (including themselves), and a broader approach might have been of value. By adding a more detailed discussion concerning, for example, the treatment choice in different histologic ovarian cancer types, or BRCA pos/neg patients, the paper would be more forward-looking, in my opinion. Further, surgery in recurrent ovarian cancer was not mentioned.

Answer: Thank you for your interesting comment and for your important suggestions. The discussion on treatment pathway has been implemented with details on tailoring of treatment in relation to tumor histology (page7, lines 235-243) and more recent evidence on association of HIPEC treatment with tumor genetic profiling, with an overall implementation of manuscript references (page 8, line 285-310).. Also, a section of the discussion focused on recurrent disease has been added, as requested (page 9 from line 338).

Back to TopTop